Mon, Aug. 24, 4:29 PM
- The Nasdaq opened down 7.5%, furiously rallied almost to breakeven, and then sold off again in the afternoon to close down 3.8%. Some tech stocks managed to rise nonetheless, while many others posted 5%+ declines.
- Major decliners included Citrix (CTXS -9.3%), Solera (SLH -8.9%), NCR (NCR -7.8%), Nuance (NUAN -6.9%), Infinera (INFN -6.4%), HomeAway (AWAY -6.6%), MagnaChip (MX -6.4%), Yandex (YNDX -7.5%), Neustar (NSR -6%), Ebix (EBIX -7.3%), SGI (SGI -8%), Monster (MWW -7.5%), Silver Spring (SSNI -6.6%), Perion (PERI -11%), and Synchronoss (SNCR -7.5%).
- Solera's decline comes 4 days after the company confirmed it's exploring strategic alternatives, and 5 days after Bloomberg reported a sale is being explored. Yandex has been hit hard in recent weeks by the ruble and crude oil's decline. Infinera is down 20% over the last 3 trading days, albeit still up 34% YTD.
- See also: Morning decliners, Chinese tech stocks, large-cap decliners
Thu, Aug. 6, 4:40 PM
- Though officially beating consensus, Nuance's (NASDAQ:NUAN) FQ3 results were in-line with the guidance provided in its July 21 pre-announcement. In its prepared remarks (.pdf), the voice recognition software giant has guided for FQ4 revenue of $497M-$513M and EPS of $0.33-$0.37 vs. a consensus of $509.4M and $0.35.
- Bookings: Net new bookings rose 47% Y/Y in FQ3 to $484.4M, aided by several "unusually large" automotive contracts and strong healthcare bookings. Over the first 3 quarters of FY15, bookings are up a modest 2% to $1.09B. In spite of the strong FQ3 performance, Nuance still only expects 1%-4% FY15 net new bookings growth.
- Segment performance: Healthcare revenue -1% Y/Y to $236.8M; op. profit of $81.8M (over half of total op. profit). Mobile/consumer -5% to $108.5M; op. profit of $27M. Enterprise nearly flat at $87M; op. profit of $24.9M. Imaging -8% to $56.3M; op. profit of $21.8M. Total FQ3 organic revenue growth was -3% (+1% exc. forex).
- Financials: Op. margin rose 290 bps Y/Y to 26.4%. A 210 bps increase in gross margin to 63.1% helped, as did a $3.2M drop in operating expenses to $179.2M. $122.4M was spent on buybacks. Nuance ended FQ3 with $489M in cash/investments, and $2.12B in debt.
- Shares have dropped to $17.00 AH.
- FQ3 results, PR
Wed, Jul. 22, 5:41 PM
Tue, Jul. 21, 10:09 PM
- Nuance (NASDAQ:NUAN) now expects to report FQ3 (calendar Q2) revenue of $485M-$489M and EPS of $0.31-$0.32. That's better than prior guidance of $468M-$482M and $0.25-$0.29, and a consensus of $477M and $0.28. Formal FQ3 results arrive on Aug. 6.
- The voice recognition software giant also announces Tom Beaudoin, its CFO since 2008, is leaving at month's end to "pursue an opportunity at a smaller, privately held company." Finance SVP/chief accounting officer Daniel Tempesta will replace him.
- Shares rose to $17.59 in AH trading. The 52-week high is $18.66.
Tue, Jul. 21, 5:40 PM
Wed, Jun. 3, 9:51 AM
Thu, May 7, 4:23 PM
- Nuance (NASDAQ:NUAN) uses its FQ2 report to state it's adding $500M to its buyback, bringing its total aurhorization to $591.7M. $120.3M was spent in FQ2 to buy back 8.56M shares at an average price of $14.06.
- The company guided in its prepared remarks (.pdf) for FY15 (ends Sep. '15) revenue of $1.94B-$1.98B and EPS of $1.13-$1.23; the former is unfavorable to a $1.98B consensus, but the latter is above a $1.12 consensus. FQ3 guidance is for revenue of $468M-$482M and EPS of $0.25-$0.29, mostly below a consensus of $487.7M and $0.28.
- FY15 net new bookings growth guidance has been cut to 1%-4% from a prior 4%-5%. A strong dollar is now expected to have a $55M impact on FY15 revenue ($10M worse than previously forecast), and a $32M impact on net new bookings.
- Net new bookings fell 27% Y/Y in FQ2 to $304.7M, thanks largely to a $100M connected car deal booked a year ago. However, the deferred revenue balance rose 26.3% Y/Y to $637.8M.
- Healthcare revenue (47% of total revenue) -4% Y/Y; mobile/consumer +9%, enterprise -7%; imaging -7%. In addition to buybacks, EPS got a lift from a 7% Y/Y drop in GAAP operating expenses to $245.3M.
- Nuance has risen to $15.82 AH.
- FQ2 results, PR
Thu, May 7, 4:04 PM
Thu, Apr. 23, 2:28 PM
- Nuance (NASDAQ:NUAN) is sharply higher on volume of 2.19M shares (above a 3-month daily average of 1.89M). Shares (largely range-bound this year) have risen to their highest levels since December.
- Earlier today, the voice recognition software/services provider announced its FQ2 (calendar Q1) report would arrive on May 7. With Nuance having provided light guidance in February (thanks in part to soft mobile/consumer demand), expectations are low.
Thu, Mar. 19, 1:09 PM
- As part of a broader transfer of coverage for healthcare tech names, Baird has upgraded Cerner (CERN +3.3%) to Outperform, and hiked its target by $12 to $77. Allscripts (MDRX +3.6%) has been launched at Outperform, and assigned a $16 target. Quality Systems (QSII -1.1%) has been downgraded to Neutral.
- Also: Allscripts has announced it's partnering with healthcare voice recognition software vendor NoteSwift to resell NoteSwift's offerings with Allscripts' Professional EHR health record software, in response to customer demand. Nuance's (NASDAQ:NUAN) Dragon Medical powers NoteSwift's software.
- Cerner has made new highs. RBC downgraded Quality Systems last week.
Thu, Feb. 5, 5:35 PM
- Though it beat FQ1 estimates, Nuance (NASDAQ:NUAN) has guided in its prepared remarks (.pdf) for FQ2 revenue of $459M-$475M and EPS of $0.22-$0.26, below a consensus of $499.5M and $0.27. FY15 (ends Sep. '15) guidance is for revenue of $1.907B-$1.957B and EPS of $1.08-$1.18; the latter is in-line with a $1.13 consensus, but the former is below a $2.05B consensus.
- Net new bookings (excludes renewal bookings) fell 5.5% Y/Y in FQ1 to $303.8M. Nuance calls the 15 net new bookings it recorded "disappointing," and (thanks in part to forex) is lowering its FY15 net new bookings growth guidance to 4%-5% from 6%-8%.
- Thanks to the shift towards cloud/subscription revenue streams, the deferred revenue balance rose 28.2% to $484.3M. On-demand solutions made up 36% of revenue.
- Healthcare organic revenue growth was flat, mobile/consumer was -5%, enterprise -4%, and imaging -9%. Total organic growth was -3%. GAAP operating expenses rose by less than $300K Y/Y to $278.2M.
- Regarding mobile/consumer, Nuance notes mobile cloud transactions rose 66% Y/Y to 3.98B. But it also cautions it has "experienced pressure in the mobile phone industry as market share shifts among leading vendors and emerging companies, largely from China."
- FQ1 results, PR
Fri, Jan. 9, 9:25 AM
- "We do not see NUAN as a potential acquisition candidate, and see growth and margins challenged," writes Goldman's Greg Dunham, downgrading the voice recognition software/services giant to Sell.
- Goldman's LBO model suggests a -1% IRR for a Nuance LBO under its base-case scenario, compared with a 20% IRR for enterprise software vendors CommVault and Informatica.
- The WSJ reported back in June Nuance had talked with Samsung and P-E firms about a potential sale. Speculation that Carl Icahn would push the company to sell itself has been around for some time.
- Shares have made new 52-week lows. They now go for ~3x estimated FY15 (ends Sep. '15) EV/sales.
Nov. 25, 2014, 9:15 AM
Nov. 24, 2014, 5:43 PM
Nov. 24, 2014, 4:22 PM
- Nuance (NASDAQ:NUAN) guides in its prepared remarks (.pdf) for FQ1 revenue of $480M-$490M and EPS of $0.21-$0.23, below a consensus of $500.6M and $0.27. FY15 (ends Sep. '15) guidance is healthier: Revenue of $2.02B-$2.08B and EPS of $1.10-$1.20 vs. a consensus of $2.07B and $1.15.
- Bookings rose 24.5% Y/Y in FQ4 to $497.7M, an improvement from FQ3's 16.7% growth. FY14 bookings totaled $2.44B, +27.4% Y/Y and above guidance of $2.35B-$2.4B. 6%-8% net new bookings growth is expected in FY15.
- Healthcare revenue (responsible for nearly half of all op. profit) +3% Y/Y to $238.3M; mobile & consumer -3% to $116.9M; enterprise -4% to $95.6M; imaging +9% to $69.5M.
- Healthcare growth improved from FQ3's -2% thanks to on-demand, diagnostics, and Clintegrity sales. Mobile & consumer benefited from auto growth, and was hurt by weak phone-related sales. Though enterprise revenue is soft, bookings (boosted by Nina) are healthier.
- No buybacks took place in FQ4. GAAP opex rose 5% Y/Y to $282.2M. Thanks to a shift towards subscriptions/recurring revenue streams, Nuance's deferred revenue balance rose 32% Y/Y to $548.1M.
- FQ4 results, PR
Nov. 24, 2014, 4:04 PM
NUAN vs. ETF Alternatives
Other News & PR